BioCentury | Dec 31, 2020
Finance

Dec. 30 Quick Takes: Transcenta leads year-end crop of China venture rounds

...personalized COVID-19 vaccine. Aivita is also submitting a marketing application in Japan for its melanoma therapy.Inhibikase...
...expand its R&D team and construct a biochemical laboratory for internal compound testing. BC Staff ImmunoChina Eccogene Aegicare (Shenzhen) Technology Inhibikase Aivita...
BioCentury | Jan 18, 2018
Emerging Company Profile

Computing brain entry

...Ltd. announced start of a Phase I study of SUN-K0706, a BCR-ABL tyrosine kinase inhibitor. Inhibikase Therapeutics Inc.’s...
...Eun Kim Patents: None issued Companies and Institutions Mentioned 1st Biotherapeutics Inc., Seongnam, South Korea Inhibikase Therapeutics Inc....
BioCentury | Dec 14, 2017
Product R&D

Opening doors in PML

...disclosed: the gene-editing candidate EBT103 from Excision Biotherapeutics Inc. and IkT-01427, a BCR-ABL inhibitor from Inhibikase Therapeutics Inc....
...benchmarks.” Companies and Institutions Mentioned Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Excision Biotherapeutics Inc. Philadelphia, Pa Inhibikase Therapeutics Inc....
BioCentury | May 26, 2014
Clinical News

IkT-001Pro regulatory update

...is the active ingredient in the company's IkT-001Pro, which is in preclinical testing for PML. Inhibikase...
...and side effects of imatinib therapy. Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets Gleevec imatinib. Inhibikase Therapeutics Inc....
BioCentury | Nov 25, 2013
Company News

Inhibikase board of directors update

Inhibikase Therapeutics Inc. , Atlanta, Ga. Business: Infectious Appointed: Anthony Zook, formerly CEO and a director of Vivus Inc. WIR Staff Infectious...
Items per page:
1 - 5 of 5
BioCentury | Dec 31, 2020
Finance

Dec. 30 Quick Takes: Transcenta leads year-end crop of China venture rounds

...personalized COVID-19 vaccine. Aivita is also submitting a marketing application in Japan for its melanoma therapy.Inhibikase...
...expand its R&D team and construct a biochemical laboratory for internal compound testing. BC Staff ImmunoChina Eccogene Aegicare (Shenzhen) Technology Inhibikase Aivita...
BioCentury | Jan 18, 2018
Emerging Company Profile

Computing brain entry

...Ltd. announced start of a Phase I study of SUN-K0706, a BCR-ABL tyrosine kinase inhibitor. Inhibikase Therapeutics Inc.’s...
...Eun Kim Patents: None issued Companies and Institutions Mentioned 1st Biotherapeutics Inc., Seongnam, South Korea Inhibikase Therapeutics Inc....
BioCentury | Dec 14, 2017
Product R&D

Opening doors in PML

...disclosed: the gene-editing candidate EBT103 from Excision Biotherapeutics Inc. and IkT-01427, a BCR-ABL inhibitor from Inhibikase Therapeutics Inc....
...benchmarks.” Companies and Institutions Mentioned Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Excision Biotherapeutics Inc. Philadelphia, Pa Inhibikase Therapeutics Inc....
BioCentury | May 26, 2014
Clinical News

IkT-001Pro regulatory update

...is the active ingredient in the company's IkT-001Pro, which is in preclinical testing for PML. Inhibikase...
...and side effects of imatinib therapy. Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets Gleevec imatinib. Inhibikase Therapeutics Inc....
BioCentury | Nov 25, 2013
Company News

Inhibikase board of directors update

Inhibikase Therapeutics Inc. , Atlanta, Ga. Business: Infectious Appointed: Anthony Zook, formerly CEO and a director of Vivus Inc. WIR Staff Infectious...
Items per page:
1 - 5 of 5